Accéder au contenu
Merck

Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.

The New England journal of medicine (2015-07-30)
Sudheer Kumar Gara, Li Jia, Maria J Merino, Sunita K Agarwal, Lisa Zhang, Maggie Cam, Dhaval Patel, Electron Kebebew
RÉSUMÉ

Familial nonmedullary thyroid cancer accounts for 3 to 9% of all cases of thyroid cancer, but the susceptibility genes are not known. Here, we report a germline variant of HABP2 in seven affected members of a kindred with familial nonmedullary thyroid cancer and in 4.7% of 423 patients with thyroid cancer. This variant was associated with increased HABP2 protein expression in tumor samples from affected family members, as compared with normal adjacent thyroid tissue and samples from sporadic cancers. Functional studies showed that HABP2 has a tumor-suppressive effect, whereas the G534E variant results in loss of function.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MISSION® esiRNA, targeting human HABP2